WebMay 10, 2024 · THIS FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE (the “Note”) is executed this 10th day of May 2024, by Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and Leonard Mazur (the “Holder”). 1. Instrument.The Company, for value received, hereby promises to pay to the order of Holder in lawful money of the … WebWelcome to CitiusTech. The future of healthcare and life sciences will be patient and consumer centric, convergent and digitally driven, powered by next-gen technology, analytics and AI. Digital innovation will play a …
Citius Pharmaceuticals Inc (CTXR) Stock Price & News - Google
WebApr 11, 2024 · Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. WebDec 9, 2024 · General Business All General Business Awards Commercial Real Estate Corporate Expansion Earnings Environmental, Social and Governance (ESG) Human Resource & Workforce Management Licensing New... incarnation\u0027s y6
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 ...
WebDec 22, 2024 · Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ... WebApr 3, 2024 · Citius CEO Leonard Mazur stated that the company is committed to maximizing the value of I/ONTAK and advancing its pipeline. Maxim Group was selected for its strong track record in executing... WebMar 30, 2024 · Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on … incarnation\u0027s y4